Trial Profile
A multi-centre, double blind, randomised, placebo-controlled, parallel group, phase II trial to determine the efficacy of intra-nodular injection of anti-TNF to control disease progression in early Dupuytren's disease, with a dose response
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Aug 2023
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Dupuytren's contracture
- Focus Pharmacodynamics; Proof of concept; Registrational
- Acronyms RIDD
- 03 Aug 2023 According to a 180 Life Sciences media release, the company has submitted a request to the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) for a follow up scientific advice meeting. A meeting with the MHRA is anticipated to take place in late Q3 of 2023 with the written responses anticipated to be received prior to year end.
- 25 Jan 2023 According to a 180 Life Sciences media release, the company announces publication of review article in The Journal of Hand Surgery (European Volume), which contains this study results.
- 25 Jan 2023 Results published in the 180 Life Sciences media release